Clinical Trials Browser

Phase 2/3 × Colorectal Neoplasms × spartalizumab × Clear all

NCT06280495 2026-04-20

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms